

Table SI. Alleles of 16 short tandem repeat loci in PE8 cell line.

Marker	Allele 1	Allele 2
D8S1179	11	13
D21S11	29	29
D7S820	11	11
CSF1PO	11	12
D3S1358	18	18
TH01	9	9
D13S317	11	13
D16S539	12	13
D2S1338	17	20
D19S433	13	13
vWA	14	18
TPOX	8	10
D18S51	10	12
AMEL	X	Y
D5S818	11	13
FGA	24	24

Table SII. Alleles of 16 short tandem repeat loci in PE9 cell line.

Marker	Allele 1	Allele 2
D8S1179	9	17
D21S11	30	31
D7S820	10	10
CSF1PO	11	12
D3S1358	15	18
TH01	6	9
D13S317	8	8
D16S539	9	9
D2S1338	17	25
D19S433	13	14
vWA	16	17
TPOX	8	8
D18S51	14	14
AMEL	X	Y
D5S818	11	12
FGA	23	25

Table SIII. CI values obtained from the different combinations of treatments with APR-246 and DZ-Nep.

A, GOS-3 cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+DZ-Nep		PREAPR+DZ-Nep48H		PREDZ-Nep+APR48H	
APR-246	DZ-Nep	Fa	CI value	Fa	CI value	Fa	CI value
62	5	0.843	1.021	0.840	0.931	0.770	1.132
66	10	0.884	0.951	0.827	0.986	0.817	1.058
70	20	0.885	1.006	0.865	0.956	0.832	1.074
74	40	0.890	1.042	0.882	0.964	0.853	1.056
78	80	0.893	1.085	0.884	1.009	0.854	1.110
B, MOG-G-CCM cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+DZ-Nep		PREAPR+DZ-Nep48H		PREDZ-Nep+APR48H	
APR-246	DZ-Nep	Fa	CI value	Fa	CI value	Fa	CI value
33	5	0.834	0.840	0.010	194.110	0.000	20120000
35	10	0.871	0.872	0.052	6.069	0.001	92862.200
37	20	0.926	0.882	0.188	1.208	0.002	63703.500
39	40	0.940	0.915	0.473	0.589	0.010	840.722
41	80	0.944	0.956	0.769	0.335	0.011	23.153
C, U87MG cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+DZ-Nep		PREAPR+DZ-Nep48H		PREDZ-Nep+APR48H	
APR-246	DZ-Nep	Fa	CI value	Fa	CI value	Fa	CI value
33	5	0.271	1.061	0.245	1.221	0.000	6957.970
35	10	0.371	1.063	0.265	1.267	0.001	443.598
37	20	0.452	1.087	0.306	1.175	0.002	482.054
39	40	0.555	1.093	0.403	1.050	0.011	57.024
41	80	0.859	0.902	0.427	1.090	0.051	10.526
D, LN405 cells							

Dose, mM		Combined treatments		Pretreatments			
		APR+DZ-Nep		PREAPR+DZ-Nep48H		PREDZ-Nep+APR48H	
APR-246	DZ-Nep	Fa	CI value	Fa	CI value	Fa	CI value
70	5	0.628	0.963	0.052	12.490	0.216	1.136
74	10	0.677	0.975	0.165	1.215	0.225	1.194
78	20	0.742	0.965	0.217	1.122	0.242	1.231
82	40	0.815	0.931	0.235	1.226	0.322	1.116
86	80	0.818	0.974	0.252	1.370	0.377	1.080
E, LN405-TMZR cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+DZ-Nep		PREAPR+DZ-Nep48H		PREDZ-Nep+APR48H	
APR-246	DZ-Nep	Fa	CI value	Fa	CI value	Fa	CI value
62	5	0.662	1.014	0.199	4.000	0.243	1.520
66	10	0.722	1.044	0.199	7.041	0.244	2.092
70	20	0.753	1.091	0.237	4.464	0.293	1.194
74	40	0.781	1.140	0.311	1.757	0.318	1.124
78	80	0.795	1.205	0.365	1.293	0.321	1.303

APR-246+DZ-Nep, double treatment with APR-246 and DZ-Nep for 72 h; PREAPR-246+DZ-Nep48H, pretreatment of APR-246 for 24 h followed by post-treatment with DZ-Nep for 48 h; PREDZ-Nep+APR-24648H, pretreatment of DZ-Nep for 24 h followed by post-treatment with APR-246 for 48 h; CI, Combinational Index; Fa: fractions affected.

Table SIV. CI values obtained from the different combinations of treatments with APR-246 and panobinostat.

A, GOS-3 cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Panob		PREAPR+Panob48H		PREPanob+APR48H	
APR-246	Panob	Fa	CI value	Fa	CI value	Fa	CI value
62	0.01	0.862	0.965	0.811	0.967	0.802	1.040
66	0.02	0.867	1.010	0.829	0.999	0.858	0.927
70	0.04	0.889	0.988	0.859	0.998	0.868	0.947
74	0.08	0.910	0.957	0.871	1.044	0.877	0.968
78	0.16	0.915	0.986	0.908	1.002	0.886	0.982
B, MOG-G-CCM cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Panob		PREAPR+Panob48H		PREPanob+APR48H	
APR-246	Panob	Fa	CI value	Fa	CI value	Fa	CI value
33	0.01	0.823	0.905	0.010	58.722	0.081	2.659
35	0.02	0.871	0.966	0.294	1.158	0.153	2.170
37	0.04	0.926	1.002	0.423	0.967	0.281	1.761
39	0.08	0.940	1.167	0.479	1.093	0.914	0.794
41	0.16	0.949	1.270	0.802	0.421	0.938	0.804
C, U87MG cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Panob		PREAPR+Panob48H		PREPanob+APR48H	
APR-246	Panob	Fa	CI value	Fa	CI value	Fa	CI value
33	0.01	0.891	0.693	0.342	1.190	0.081	243.190
35	0.02	0.912	0.713	0.358	1.335	0.153	36.338
37	0.04	0.920	0.748	0.549	0.914	0.281	4.952
39	0.08	0.955	0.725	0.618	0.920	0.914	0.216

41	0.16	0.966	0.737	0.729	0.897	0.938	0.202
D, LN405 cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Panob		PREAPR+Panob48H		PREPanob+APR48H	
APR-246	Panob.	Fa	CI value	Fa	CI value	Fa	CI value
70	0.01	0.712	0.969	0.025	1.532	0.298	0.993
74	0.02	0.719	1.087	0.057	1.583	0.346	0.985
78	0.04	0.726	1.279	0.152	1.549	0.552	0.784
82	0.08	0.783	1.498	0.339	1.546	0.650	0.724
86	0.16	0.841	1.851	0.690	1.375	0.784	0.611
E, LN405-TMZR cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Panob		PREAPR+Panob48H		PREPanob+APR48H	
APR-246	Panob	Fa	CI value	Fa	CI value	Fa	CI value
62	0.01	0.323	1.347	0.138	1.590	0.182	1.521
66	0.02	0.424	1.401	0.194	1.467	0.208	1.563
70	0.04	0.823	1.076	0.340	1.033	0.403	0.794
74	0.08	0.859	1.127	0.508	0.765	0.528	0.640
78	0.16	0.860	1.271	0.655	0.602	0.804	0.353

APR-246+Panob, double treatment with APR-246 and panobinostat for 72 h; PREAPR-246+Panob48H, pretreatment of APR-246 for 24 h followed by post-treatment with panobinostat for 48 h; PREPanob+APR-24648H, pretreatment of panobinostat for 24 h followed by post-treatment with APR-246 for 48 h; CI, Combinational Index; Panob, panobinostat; Fa, fractions affected.

Table SV. CI values obtained from the different combinations of treatments with APR-246 and temozolomide.

A, GOS-3 cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Temoz		PREAPR+Temoz48H		PRETemoz+APR48H	
APR-246	Temoz	Fa	CI value	Fa	CI value	Fa	CI value
62	12.5	0.829	1.063	0.818	0.944	0.758	1.165
66	25.0	0.836	1.109	0.818	1.005	0.833	1.008
70	50.0	0.863	1.086	0.853	0.985	0.846	1.025
74	100.0	0.896	1.019	0.881	0.967	0.850	1.068
78	200.0	0.911	1.003	0.886	0.529	0.860	1.087
B, MOG-G-CCM cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Temoz		PREAPR+Temoz48H		PRETemoz+APR48H	
APR-246	Temoz	Fa	CI value	Fa	CI value	Fa	CI value
33	12.5	0.354	1.002	0.009	17.506	0.033	4.083
35	25.0	0.389	1.061	0.057	3.050	0.159	1.321
37	50.0	0.412	1.134	0.135	1.783	0.177	1.485
39	100.0	0.814	1.006	0.167	1.904	0.206	1.648
41	200.0	0.895	1.007	0.276	1.453	0.240	1.851
C, U87MG cells							
Dose, mM		Combined treatments		Pretreatments			

		APR+Temoz		PREAPR+Temoz48H		PRETemoz+APR48H	
APR-246	Temoz	Fa	CI value	Fa	CI value	Fa	CI value
33	12.5	0.281	1.310	0.366	0.899	0.019	26.222
35	25.0	0.317	1.283	0.375	0.949	0.054	7.721
37	50.0	0.344	1.329	0.470	0.944	0.080	7.262
39	100.0	0.387	1.300	0.592	0.929	0.085	12.055
33	200.0	0.281	1.310	0.366	0.899	0.019	26.222
D, LN405 cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Temoz		PREAPR+Temoz48H		PRETemoz+APR48H	
APR-246	Temoz	Fa	CI value	Fa	CI value	Fa	CI value
70	12.5	0.687	0.914	0.127	1.217	0.288	1.004
74	25.0	0.703	0.953	0.176	1.189	0.322	1.015
78	50.0	0.719	0.990	0.232	1.188	0.378	0.991
82	100.0	0.804	0.947	0.315	1.139	0.446	0.952
86	200.0	0.814	0.981	0.408	1.106	0.456	1.003
E, LN405-TMZR cells							
Dose, mM		Combined treatments		Pretreatments			
		APR+Temoz		PREAPR+Temoz48H		PRETemoz+APR48H	
APR-246	Temoz	Fa	CI value	Fa	CI value	Fa	CI value

62	12.5	0.548	1.063	0.259	1.237	0.199	1.846
66	25.0	0.686	1.053	0.266	1.544	0.210	2.296
70	50.0	0.701	1.107	0.352	0.960	0.255	1.892
74	100.0	0.704	1.169	0.384	0.954	0.206	6.467
78	200.0	0.745	1.200	0.439	0.510	0.334	1.716

APR-246+Temoz, double simultaneous treatment of APR-246 and temozolomide for 72 h; PREAPR-246+Temoz48H, pretreatment of APR-246 for 24 h followed by post-treatment with temozolomide for 48 h; PRETemoz+APR-24648H, pretreatment of temozolomide for 24 h followed by post-treatment with APR-246 for 48 h; CI: Combinational Index; Temoz, temozolomide; Fa, fractions affected.

Table SVI. CI values obtained from APR-246, panobinostat and temozolomide triple combination.

A, GOS-3 cells				
Dose, mM			Experimental CI	
APR-246	Panob	Temoz	Fa	CI value
20.666	3.333	4.166	0.830	0.354
22.000	6.667	8.333	0.840	0.366
23.333	13.333	16.666	0.872	0.351
24.666	26.667	33.333	0.879	0.362
26.000	53.333	66.666	0.924	0.314
B, MOG-G-CCM cells				
Dose, mM			Experimental CI	
APR-246	Panob	Temoz	Fa	CI value
11.000	3.333	4.166	0.277	0.469
11.666	6.667	8.333	0.315	0.583
12.333	13.333	16.666	0.778	0.423
13.000	26.667	33.333	0.815	0.506
13.666	53.333	66.666	0.828	0.671
C, U87MG cells				
Dose, mM			Experimental CI	
APR-246	Panob	Temoz	Fa	CI value
11.000	3.333	4.166	0.822	0.251
11.666	6.667	8.333	0.839	0.317
12.333	13.333	16.666	0.877	0.270

13.000	26.667	33.333	0.916	0.268
13.666	53.333	66.666	0.946	0.265
D, LN405 cells				
Dose, mM			Experimental CI	
APR-246	Panob	Temoz	Fa	CI value
23.333	3.333	4.166	0.822	0.251
24.666	6.667	8.333	0.839	0.316
26.000	13.333	16.666	0.877	0.270
27.333	26.667	33.333	0.916	0.268
28.666	53.333	66.666	0.946	0.265
E, LN405-TMZR cells				
Dose, mM			Experimental CI	
APR-246	Panob	Temoz	Fa	CI value
20.666	3.333	4.166	0.262	0.668
22.000	6.667	8.333	0.298	0.666
23.333	13.333	16.666	0.386	0.611
24.666	26.667	33.333	0.717	0.460
26.000	53.333	66.666	0.856	0.427

CI, Combinational Index; Panob, Panobinostat; Temoz, temozolomide; Fa, fractions affected.

Table SVII. CI values obtained from APR-246, DZ-Nep and panobinostat triple combination.

A, GOS-3 cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Panob	Fa	CI value
20.666	1.666	3.333	0.869	0.314
22.000	3.333	6.667	0.872	0.331
23.333	6.666	13.333	0.877	0.345
24.666	13.333	26.667	0.893	0.343
26.000	26.666	53.333	0.898	0.355
B, MOG-G-CCM cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Panob	Fa	CI value
11.000	1.666	3.333	0.463	0.387
11.666	3.333	6.667	0.576	0.425
12.333	6.666	13.333	0.855	0.379
13.000	13.333	26.667	0.878	0.442
13.666	26.666	53.333	0.913	0.513
C, U87MG cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Panob	Fa	CI value
11.000	1.666	3.333	0.822	0.251
11.666	3.333	6.667	0.839	0.316
12.333	6.666	13.333	0.877	0.270

13.000	13.333	26.667	0.916	0.268
13.666	26.666	53.333	0.946	0.265
D, LN405 cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Panob	Fa	CI value
23.333	1.666	3.333	0.446	0.216
24.666	3.333	6.667	0.509	0.249
26.000	6.666	13.333	0.747	0.247
27.333	13.333	26.667	0.830	0.301
28.666	26.666	53.333	0.835	0.460
E, LN405-TMZR cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Panob	Fa	CI value
20.666	1.666	3.333	0.207	0.829
22.000	3.333	6.667	0.249	0.964
23.333	6.666	13.333	0.480	0.600
24.666	13.333	26.667	0.810	0.412
26.000	26.666	53.333	0.879	0.411

CI, Combinational Index; Panob, panobinostat; Fa, fractions affected.

Table SVIII. CI values obtained from APR-246, DZ-Nep and temozolomide triple combination.

A, GOS-3 cells				
Dose mM			Experimental CI	
APR-246	DZ-Nep	Temoz	Fa	CI value
20.666	1.666	4.166	0.833	0.351
22.000	3.333	8.333	0.840	0.366
23.333	6.666	16.666	0.853	0.374
24.666	13.333	33.333	0.866	0.37426
26.000	26.666	66.666	0.877	0.386
B, MOG-G-CCM cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Temoz	Fa	CI value
11.000	1.666	4.166	0.229	0.375
11.666	3.333	8.333	0.251	0.412
12.333	6.666	16.666	0.298	0.442
13.000	13.333	33.333	0.329	0.494
13.666	26.666	66.666	0.340	0.598
C, U87MG cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Temoz	Fa	CI value
11.000	1.666	4.166	0.489	0.312
11.666	3.333	8.333	0.503	0.336
12.333	6.666	16.666	0.622	0.332

13.000	13.333	33.333	0.797	0.306
13.666	26.666	66.666	0.812	0.323
D, LN405 cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Temoz	Fa	CI value
23.333	1.666	4.166	0.476	0.174
24.666	3.333	8.333	0.495	0.183
26.000	6.666	16.666	0.561	0.184
27.333	13.333	33.333	0.668	0.176
28.666	26.666	66.666	0.794	0.161
E, LN405-TMZR cells				
Dose, mM			Experimental CI	
APR-246	DZ-Nep	Temoz	Fa	CI value
20.666	1.666	4.166	0.353	0.467
22.000	3.333	8.333	0.358	0.559
23.333	6.666	16.666	0.382	0.652
24.666	13.333	33.333	0.404	0.792
26.000	26.666	66.666	0.530	0.665

CI, Combinational Index; Temoz, temozolomide; Fa, fractions affected.